Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542958 · ClinicalTrials.gov registry record · Phase 1
Study of NK012 in Patients With Refractory Solid Tumors
A Phase 1 study of Cancer, sponsored by Nippon Kayaku Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT00542958 is a Phase 1 study of Cancer that has completed, run by Nippon Kayaku Co.. The registered enrollment target is 39 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00542958, a Phase 1 study of Cancer, has completed, sponsored by Nippon Kayaku Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether NK012 is safe and effective in the treatment of refractory solid tumors
Conditions Studied
Interventions
- DRUG NK012
Study Locations (1)
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00542958
The ClinicalTrials.gov registry entry for NCT00542958 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Nippon Kayaku Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which NK012 is the first listed.
NCT00542958 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00542958 about?
NCT00542958 is a clinical study titled "Study of NK012 in Patients With Refractory Solid Tumors". The purpose of this study is to determine whether NK012 is safe and effective in the treatment of refractory solid tumors
What is the current status of trial NCT00542958?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2007-03. Estimated completion is 2011-12.
What conditions does trial NCT00542958 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00542958?
The interventions under investigation include: NK012 (DRUG).
Who is sponsoring clinical trial NCT00542958?
This trial is sponsored by Nippon Kayaku Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00542958 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.